NCT00396006已完成4 期
The Effect of Augmentation Therapy With ARALAST Fraction IV-1 (ARALAST) Alpha1-Proteinase Inhibitor (α1-PI) on the Level of α1-PI and Other Analytes in the Bronchoalveolar (BAL) Epithelial Lining Fluid (ELF)
Baxalta now part of Shire5 个研究点 分布在 2 个国家目标入组 21 人开始时间: 2006年10月27日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 21
- 试验地点
- 5
- 主要终点
- Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level
研究概览
简要总结
The purpose of this study is to evaluate the effects of weekly augmentation therapy with ARALAST Fraction IV-1 (Fr IV-1) on epithelial lining fluid (ELF) alpha 1-proteinase inhibitor levels and other ELF analytes and to assess the safety of the treatment. Eligible subjects with a diagnosis of severe congenital alpha 1-antitrypsin deficiency will receive 8 consecutive weekly treatments with 60 mg/kg/week of functional ARALAST Fr IV-1 administered intravenously. The efficacy and safety assessments will include two bronchoscopies with bronchoalveolar lavage on study initiation and on study termination and multiple imaging and laboratory safety assessments. Each subject will participate for a minimum of 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent.
- •Male or female 18 years of age or older.
- •Documented, endogenous serum α1-PI level < 40 mg/dL measured at screening (unless otherwise approved by the Sponsor) after a minimum of 28-day washout of any prior replacement therapy (if applicable).
- •Phenotype Pi Z (which includes Pi*Z/Z, Pi*Z/Null, or Pi*Malton/Z), or Pi*Null/Null.
- •Pulmonary functions at screening meeting the following criteria:
- •Forced expiratory volume at 1 second (FEV1) >= 50% of predicted value; or
- •FEV1 > 35% of predicted value and diffusing capacity for carbon monoxide > 45% of predicated value, with no supplemental oxygen therapy and < 3 pulmonary exacerbations or bronchitis requiring antibiotics/corticosteroids within the past 12 months).
- •For any female of childbearing potential, a negative urine test for pregnancy within 7 days prior to the first bronchoalveolar lavage (BAL) visit and agreement to employ adequate birth control measures for the duration of the study.
- •No clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG) performed at the screening visit (ECG previously obtained within the past 12 months may be used, if available).
- •Laboratory results obtained at the screening visit, meeting the following criteria:
- •Serum alanine aminotransferase (ALT) <= 2 times upper limit of normal (ULN)
- •Serum aspartate aminotransferase (AST) <= 2 times ULN
- •Serum total bilirubin <= 2 times ULN
- •Proteinuria < +2 on dipstick analysis
- •Serum creatinine <= 1.5 times ULN
- •Absolute neutrophil count (ANC) >= 1500 cells/mm3
- •Hemoglobin (Hgb) >= 10.0 g/dL
- •Platelet count >= 105/mm3
- •If the subject is treated with respiratory medications, such as inhaled bronchodilators or inhaled corticosteroids, or other chronic medications for the treatment of the subjects´s other medical condition(s), the subject's medication doses were unchanged for at least 14 days prior to the baseline BAL visit.
排除标准
- •Clinically significant pulmonary impairment, other than chronic pulmonary disease (COPD).
- •The subject has received any alpha 1 proteinase inhibitor (α1-PI) augmentation therapy (e.g., Prolastin, Zemaira, Aralast, or an investigational α1-PI, by any route including intravenous and inhaled) within 28 days prior to screening.
- •The subject has received an investigational drug or device within 1 month prior to screening, or the subject is currently receiving an investigational drug or device. If the subject receives another investigational drug or device after enrollment, the subjects is to be withdrawn from the trial.
- •Presence of clinical symptoms of any lower respiratory tract infection or acute pulmonary exacerbation within 14 days prior to screening.
- •The subject has a known selective Immunoglobulin A (IgA) deficiency (IgA level less than 15 mg/dL) and/or antibody against IgA.
- •The subject is pregnant or lactating, or intends to become pregnant during the course of the study.
- •The subject is not a suitable candidate for a BAL procedure.
- •Moderate or severe bronchiectasis (total daily sputum production > 10 mL).
- •Clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance.
- •Prior history of adverse reaction to local anaesthetics, sedatives, pain control drugs, and other medication employed at the study center for perioperative care associated with the BAL procedure.
- •Long-term use of oral or parenteral glucocorticosteroid within 28 days prior to screening.
结局指标
主要结局
Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level
时间窗: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Median change BAL ELF antigenic α1-PI level the from baseline to post-treatment
Number of Changes in the Rate of Infusion
时间窗: During 8 consecutive weeks of treatment
Number of decreases in the rate or discontinuations of infusion at 0.2 mL/kg/min
The Number of Adverse Events (AEs) Related to the Infusion of ARALAST Fr. IV 1 Administered at a Rate of 0.2 mL/kg/Min
时间窗: During 8 consecutive weeks of treatment
次要结局
- Change in in the Ratio of BAL ELF α1-PI to Human Neutrophil Elastase (HNE) Complex Concentration(BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks))
- Clinically Significant Changes in Vital Signs From Pre- to Post-Infusion(During 8 consecutive weeks of infusion)
- Ratio of Post- to Pre-treatment BAL ELF Antineutrophil Elastase Capacity (ANEC) Levels(BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks))
- Change in the α1-PI Plasma Level(Blood samples were collected at baseline and after 8 consecutive weeks of treatment)
- Change in the Plasma Antineutrophil Elastase Capacity (ANEC) Level(Blood samples were collected at baseline and after 8 consecutive weeks of treatment)
研究者
研究点 (5)
Loading locations...
相似试验
撤回
4 期
ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) StudyAlpha1-antitrypsin DeficiencyChronic Obstructive Pulmonary DiseaseNCT04440488Shire
已完成
2 期
Spondylitis Trial of Apremilast for Better Rheumatic TherapyAnkylosing SpondylitisNCT00944658Imperial College London38
已完成
不适用
Effects of Hypolipemic Treatment on AdipokinesImpaired Fasting GlycemiaHyperlipidemiaNCT01099176Medical University of Silesia78
已完成
1 期
Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV InfectionAcute HIV InfectionHIV InfectionsNCT02170246Yale University21
已完成
3 期
Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.Cardiovascular DiseasesNCT01245608Tehran University of Medical Sciences2,400